On May 6, 2024, Intensity Therapeutics, Inc. entered into a collaboration agreement with The Swiss Group for Cancer Research SAKK. Pursuant to the Collaboration Agreement, SAKK will conduct the Company?s planned Phase 2 portion of the Phase 2/3 program testing INT230-6 in combination with the standard of care treatment (chemotherapy/immunotherapy) compared to standard of care alone in women with triple negative breast cancer in presurgical (neoadjuvant) breast cancer (the ?INVINCIBLE-4 Study?) in Europe, and the Company will supply SAKK with INT230-6 as well as funding in the amount of up to approximately $3.0 million. Pursuant to the Collaboration Agreement, SAKK agreed to indemnify the Company from and against any loss, damage, reasonable costs and expense (including legal fees) incurred in connection with any claim, proceeding, or investigation arising out of, or in connection with the tasks and duties of SAKK in the INVINCIBLE-4 Study.

The Company shall be liable for claims made against SAKK that arise from the manufacture, packaging, labelling or distribution of INT230-6, subject to certain exceptions as described in the Collaboration Agreement. The Collaboration Agreement includes standard confidentiality provisions. The term of the Collaboration Agreement continues until SAKK publishes the final clinical study report from the INVINCIBLE-4 Study, unless earlier terminated in accordance with its terms. Either party may terminate the Collaboration Agreement for the other party?s material breach, subject to a specified notice and cure periods, or if the know-how generated in the INVINCIBLE-4 Study demonstrates the results generated may be of negligible scientific value, for safety reasons or on ethical grounds.

The Company also may terminate the Collaboration Agreement in the event of a significant delay in recruitment (delay greater than 12 months) that is not remedied.